An artificial intelligence-based prostate cancer diagnosis aid developed by a Korean company has received marketing authorization from overseas regulators, attracting the industry’s attention.

Deep Bio said Tuesday that its AI-based prostate cancer diagnostic auxiliary software, DeepDx Prostate, received a sales license from the Swiss medicines agency (Swissmedic) on Aug. 25.

Swissmedic is responsible for approving and supervising medicines and medical devices in Switzerland. With this approval, Deep Bio will sell DeepDx Prostate in Switzerland.

DeepDx Prostate is software that aids in cancer diagnosis by using AI to analyze Whole Slide Image (WSI) images of prostate biopsy tissue stained with hematoxylin and eosin to find cancerous areas and distinguish their severity.